Long term follow up of an Alemtuzumab (CAMPATH-1H) containing reduced intensity Allogeneic Transplant Regimen for Non-Hodgkins Lymphoma (NHL)
Reviewer: Julie Draznin Maltzman, MD
Last Modified: December 8, 2002
Presenter: Emma Morris
Presenter's Affiliation: UK Collaborative Group, United Kingdom
Type of Session: Scientific
- Campath is an antibody that targets CD 52 which is a T cell marker.
- Campath has been studied in induction therapies for myeloablative transplants.
- This study looked at Campath as additional therapy for reduced intensity allogeneic stem cell therapy for NHL.
Materials and Methods
- 93 total pts were enrolled with a predominance of men
- Median pt age was 43 years
- 46 pts had low grade or indolent lymphoma and 47 had intermediate or high grade lymphoma.
- The median number of previous therapies for all pts was 3.
- Campath was given from 9 days prior to transplant to day minus 4. A conditioning regimen of Fludarabine and Melphalan was used.
- Cyclosporin was used as GVH prophylaxis.
- 91 of the 93 pts had full engraftment. One graft rejection was seen and one death occured prior to engraftment.
- 75% of the pts experienced no GVHD. 11% had grade I GVHD, and only 4% had grade III-IV GVHD.
- Treatment related mortality at day 100 was 13% and at one year 17%.
- After 26 months of follow up overall survival was 64% for all.
- Overall survival for low grade lymphoma was 80% whereas for high grade disease survival was 33%.
- Campath use for in vivo T cell depletion reduces the incidence and severity of GVHD while getting 80% overall survival rates for low grade indolent lymphoma.
- These data imply that bone marrow T cell depletion can be adequately and efficiently done with Campath induction therapy. This may have cost and time saving implications for T cell depleted bone marrows. Further studies of this agent are indicated.
Oncolink's ASH Coverage made possible by an unrestricted Educational Grant from Ortho Biotech.